Executive summary

This study reported outcomes of 59 (64 lesions) patients with benign intracranial meningioma treated with PBT to a median total dose of 50.4 GyRBE at 1.8 GyRBE. With a median clinical and imaging follow-up of 6.3 and 4.7 years, the rates of 5-year actuarial local progression and cumulative incidence of grade 3 or greater toxicity were 6% and 2%. Two patients experienced local progression after 5 years. The 5-year actuarial overall survival rate was 87%. The authors concluded that PBT up to 50.4 GyRBE is a safe and highly effective therapy for treating benign intracranial meningioma. 

Top cancer treatments